You are here: Industry Insights > Market News > Glenmark gets USFDA approval for Clindamycin Phosphate Gel

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Glenmark gets USFDA approval for Clindamycin Phosphate Gel

expresspharmaFebruary 25, 2021

Tag: Glenmark , FDA , Acne , Clindamycin Phosphate Gel

Favorites

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (US FDA) for Clindamycin Phosphate Gel USP, 1%, the generic version of Cleocin T Gel, 1%, of Pharmacia & Upjohn.

It is an antibiotic indicated for the treatment of acne

According to IQVIA sales data for the 12 month period ending December 2020, the Cleocin T Gel, 1% market achieved annual sales of approximately $73.8 million*.

Glenmark’s current portfolio consists of 169 products authorised for distribution in the US marketplace and 42 ANDAs pending approval with the US FDA.

Previous:Celltrion develops neutralising antibody cocktail to tackle COVID-19 variant spread

Next:Parexel and NeoGenomics announce partnership to improve clinical trials

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Biotech NewswireMay 17, 2024

The expanded collaboration includes increasing adoption of the NVIDIA Clara suite of AI-powered computing platforms, software, and services in the Sartorius ecosystem.

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

PharmaSourcesMay 16, 2024

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

Glenmark gets USFDA approval for Clindamycin Phosphate Gel | Pharmasources.com

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

Nucleic Acid Medicines Manufacture, Round 2 call.

Glenmark gets USFDA approval for Clindamycin Phosphate Gel

Related News

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

You may like